Marcus Lovell Smith - Chief Executive Officer
Lisa Schimmel - Chief Financial Officer
Shailendra Kumar, M.Phil, PhD - Director of Product Development
Jeremy Schonhorn, PhD - Principal Scientist
John Connelly, PhD - Senior Scientist
Christina Swanson, PhD - Senior Scientist
Sidhartha Jain, MS - Product Engineer II
Cara Barnes, MS - Research Scientist
Peter Faust, BS - Research Scientist
Erin Coonahan, BS - Research Associate
Sahil Khullar, MS - Research Associate
Komal Sandhu, MS - Research Associate
Kendall Milkey, BS - Research Associate
Carmichael Roberts, PhD
General Partner, North Bridge Venture Partners
Marcus Lovell Smith
Chief Executive Officer, Diagnostics For All
George Whitesides, PhD
Woodford L. and Ann A. Flowers University Professor, Harvard University; Co-founder, Director and Chair of the Diagnostics for All Scientific Advisory Board
Chairman, Nano Terra, Inc.
Henrietta Holsman Fore
Chairman of the Board and Chief Executive Officer, Holsman International
William A. Holodnak, MBA
Founder and CEO, Occam Global
Senior Associate Provost and Chief Technology Development Officer, Harvard University
Dr. Hayat Sindi
Founder and CEO, i2 Institute; Member of the Shoura Council; Member of the Scientific Advisory Board to the UN Secretary-General; UNESCO Ambassador for Sciences
Venture Partner, HLM Venture Partners
Chief Executive Officer
Marcus is the CEO of Diagnostics For All. Prior to this, Marcus has directly founded and run businesses in environmental services, real estate, utility metering technology, and broadband wireless. Most recently he ran Sensable Technologies (haptics and 3D software) and Microbia Inc (industrial biotechnology). He has worked at several of the major US investment banks. He has an MA in chemistry from Oxford and the Gibbs Prize in Chemistry.
Chief Financial Officer
Lisa Schimmel joined Diagnostics for All (DFA) as CFO in August 2013. She is primarily responsible for the preparation of monthly financial statements, required reports, annual budget, annual audit, support of payroll and oversight of financial controls. Lisa is a CPA and has a wealth of experience in small to medium size non-profits as well as for-profit companies. Prior to joining DFA, she was the Director of Finance and Human Resources at the Rose Fitzgerald Kennedy Greenway Conservancy. Lisa taught financial and managerial accounting at Boston College from 1992 to 2011. While teaching, she also served on several non-profit boards and finance committees. Prior to her teaching experience she was a manager in Arthur Andersen’s Enterprise Group.
Director of Product Development
Dr. Kumar joined Diagnostics For All in March, 2010 as the Director of Product Development. Most recently, he served as the Director of Research and Development at Chembio Diagnostics and led an R&D group focused on developing point-of-care diagnostics for Syphilis, HIV, HCV and Leishmania. Prior to Chembio, Dr. Kumar worked at Matritech Inc as a Group Leader and led a team that took a breast cancer biomarker from discovery to clinical trial. Over his stay at Matritech, he initiated in-house development program for a bladder cancer diagnostic test (NMP22 BladderChek), now marketed by Alere Medical in USA and Stellar Pharmaceuticals in UK. Dr. Kumar began his career in diagnostic industries in India and worked as a Scientist at Ranbaxy Laboratories and developed numerous biochemical and immunodiagnostic products. After moving to the USA, Dr. Kumar joined Dana-Farber Cancer Institute (Harvard Medical School) and VA Medical Center (Harvard University) as an Instructor. Dr. Kumar holds a Ph.D. in Biochemistry from Aligarh Muslim University and Central Drug Research Institute, India. He has published over 25 scientific articles in peer-reviewed journals.
Dr. Schonhorn joined Diagnostics for All in April 2012 as a Principal Scientist after nearly 20 years as a developer of commercial RUO and IVD products. Prior to joining DFA, Dr. Schonhorn was a Senior Scientist with Genzyme’s Diagnostics Division. In this role, Dr. Schonhorn was the primary technical lead for the development of an FDA-approved C. difficile toxin A/B immunochromatographic device. He coordinated the activities of a multinational R&D group to develop key raw materials and develop the finished product. Dr. Schonhorn conducted verification/validation studies, and was the principal technical liaison with manufacturing to transfer the device into production. During his tenure, Dr. Schonhorn also contributed to the evaluation of new point of care technologies, and developed prototype assays for novel biomarkers of stroke and kidney injury. Before his most recent role at Genzyme, Dr. Schonhorn worked at Hemagen Diagnostics where he contributed to the development of FDA-approved assays for antiphospholipid syndrome, as well as Genzyme’s Research Products group where he developed numerous ELISA kits and DuoSets for human cytokines and growth factors. Dr. Schonhorn received his B.S. from Carnegie Mellon University, and his Ph.D. from Boston University.
Dr. Connelly joined Diagnostics For All in November 2011 as a Research Scientist. John has a broad background in nanofabrication, molecular and microbiology with more than 10 years of experience in developing nucleic acid and immunological biosensors for pathogen detection. Prior to DFA, Dr. Connelly was a postdoctoral associate in the Baeumner laboratory at Cornell University working on a collaborative project with Rheonix, Inc. As a graduate assistant, his research included the development of bioanalytical methods for waterborne parasites and viruses as well as quantitative assays for clinical markers, namely CD4+ T-cells. Dr. Connelly has a B.S., M.S. and Ph.D. in Biological Engineering with concentrations in pharmacology and food science and technology. He has published six articles in peer-reviewed journals and is a vice-chair of the 2012 Gordon Research Seminar on Bioanalytical Sensors.
Dr. Swanson joined Diagnostics for All (DFA) as a senior scientist in September 2013. Bringing a wealth of experience in lateral flow assay (LFA) development, she is primarily responsible for the advancement of DFA's nutrition deficiency assay. Dr. Swanson is trained as both an engineer and immunologist, holding a B.S. in Chemical Engineering from Cornell University, a M.Eng. in Biomedical Engineering from Cornell University and a Ph.D. in Immunology from Stanford University. Prior to joining DFA, she completed postdoctoral training and worked as a research bioengineer developing assays for radiation exposure at SRI International. During her time at SRI, she became adept at working with upconverting phosphors and introduced the usage of near-infrared dyes as valuable tools for detection in LFAs. There, Dr. Swanson enjoyed collaborating with the many physical chemists, biologists, computer scientists and engineers working on the projects. She has authored several publications and played a key role in a diversity of inventions and patent applications related to LFAs, micro-filtration and renal denervation.
Product Engineer II
Sidhartha joined Diagnostics For All in May 2010 as a Research Scientist. Prior to joining DFA, Sidhartha worked as a volunteer in the Cytology Lab at Beth Israel Deaconess Medical Center, Boston, MA. Sidhartha has a M.S. in Biomedical Engineering from Drexel University and a B.S. in Biomedical Engineering (Specializing in Mechanical Engineering) from Louisiana Tech University. Having led his senior design project, “Regeneration of Temporo-mandibular Joint Fibro-Cartilage Using Electrospun Polymer Scaffolds”, Sidhartha was awarded memberships to Alpha Eta Mu Beta (AEMB), Biomedical Engineering Honors Society and Tau Beta Pie, Engineering Honors Society at Louisiana Tech University.
Cara Barnes joined Diagnostics For All in November 2012 as a Research Associate. She has a M.S. in Analytical Chemistry from the University of Utah and a B.A. in Chemistry from Austin College. As a graduate assistant, her research focused on engineering and characterizing plasmonic nanomaterials as optical sensors. She has a broad background in bioanalytical chemistry, microfluidics, surface science, and nanoscience. Prior to joining DFA, Cara spent time living in a rural village in Ethiopia, where she taught English and science at an all-boys orphanage.
Peter joined Diagnostics For All in October 2014 as a Scientist after working 25 years in the diagnostics industry. Prior to joining DFA Peter worked at Novartis as a Senior Scientist in their Oncology division developing immunoassays for kidney markers and also qPCR, Sanger sequencing and immunohistochemical methods in the development of two oncology assays for breast and bladder cancer. Peter has a strong technical background and unique understanding of manufacturing, research and product development. Peter has a broad and diverse skill set in the areas of spectroscopy, chromatography, conjugation chemistry, assay development and assay and instrument validation. Prior to Novartis he also worked at Genzyme Diagnostics, Dyax, Bayer Diagnostics, Chiron Diagnostics and Ciba-Corning. In these settings he worked on a multitude of different platforms and assay formats including lateral flow, enzymatic, electrochemiluminescence, fluorescence, sandwich, competitive and non-competitive assays, and planar wave guide. Peter holds a B.S. from the Rochester Institute of Technology.
Erin joined Diagnostics For All in March 2013 as a Research Associate. Prior to DFA, she worked at a silk protein-based drug delivery start-up in the Boston area. Erin graduated from Tufts University in 2012 with B.S in Biomedical Engineering. While at Tufts, she led a group of students in an Engineers Without Borders project focused on providing clean water to a rural community in Eastern Uganda. She has also worked and traveled through Central and South America. In September 2014, she returned to DFA from a 6 month fellowship with a medical equipment technician training program in Honduras.
Sahil Khullar joined Diagnostics For All in June of 2012 as an Intern Scientist and further joined the team as a fulltime Research Associate in September of 2012. Prior to joining DFA, he volunteered in the Henry Wortis Lab at the Sackler School of Graduate Biomedical Sciences at Tufts University. Before that, he worked at the Center for Cardiovascular Drug Targeting at Northeastern University. He obtained his B.S. in Pharmacy from Kurukshetra University in India. He also holds a M.S. in Biomedical Sciences from Northeastern University.
Kendall grew up in New Hampshire and graduated from the University of New Hampshire in May 2014 with a B.S. in Biomedical Science. Her undergraduate research involved conducting a mutant screen in the Hrabak lab, where she selected and characterized mutant Arabidopsis thaliana plants with novel root growth to better understand signaling during plant root growth. Kendall has also worked as a veterinary technician at an equine veterinary practice.
Komal Sandhu joined DFA in March of 2013 as a Research Associate. Prior to joining DFA, she worked on several projects dealing with Lead Discovery in the area of Oncology and Autoimmune Diseases at EMD Serono. She volunteered in Henry Wortis Lab, and worked on the project Babesiosis. In India, at CSIO (CSIR affliated) she was an intern in the Nanotechnology Department, where she was graded with 'Outstanding' performance while characterizing and uniformly immobilizing antibody on the surface of optical fiber, thereby constructing a fiber optic based immunosensor. She completed her MS in Biotechnology from Northeastern University and BS in Biotechnology from Punjab Technical University, India.
Michelle Wong joined DFA in May 2014 as a Research Associate. Prior to joining DFA, she was a Research Assistant for the Cabodi Research Group at Boston University. The focus of her research was a platform for microfluidic sample preparation, for eventual point-of-care use, as well as the development of its commercial prototype. She graduated from Boston University with a B.S. in Biomedical Engineering.